Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
View Patent ↗The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.
1. A solid pharmaceutical composition for oral administration comprising:
a first population of active ingredient containing particles comprising isosorbide dinitrate, or a salt thereof, mannitol, and sugar spheres;
a second population of active ingredient containing particles comprising hydralazine, or a salt thereof, sugar spheres, and at least one stabilizer selected from the group consisting of edetic acid, salts thereof, citric acid, and salts thereof;
a third population of active ingredient containing particles comprising isosorbide dinitrate, or a salt thereof, mannitol, sugar spheres, and a protective coating selected from the group consisting of modified-release coatings and modified-release matrix coatings; and
a fourth population of active ingredient containing particles comprising hydralazine, or a salt thereof, sugar spheres, at least one stabilizer selected from the group consisting of edetic acid, salts thereof, citric acid, and salts thereof, and a coating selected from the group consisting of modified-release coatings and modified-release matrix coatings;
wherein the amount of isosorbide dinitrate contained therein is in an amount of from about 0.1 mg to about 1 g; and
wherein the amount of hydralazine contained therein is in an amount of from about 0.1 mg to about 1 g.
2. The composition according to claim 1 , wherein the protective coating is selected from the group comprising hydrophilic polymers, hydrophobic polymers, natural polymers, synthetic polymers and mixtures thereof.
3. The composition according to claim 1 , wherein at least one of the population of particles is an erodable formulation.
4. The composition according to claim 1 , wherein at least one of the protective coatings comprises a modified-release coating.
5. The composition according to claim 1 , wherein at least one of the protective coatings comprises a modified-release matrix coating.
6. The composition according to claim 2 , wherein at least one portion of the composition further comprises an enhancer.
7. The composition according to claim 1 comprising a blend of the four populations of particles contained in a hard gelatin or soft gelatin capsule.
8. The composition according to claim 7 , wherein the four populations of particles are in the form of mini-tablets and the capsule contains a mixture of the mini-tablets.
9. The composition according to claim 8 , in the form of a tablet comprising a layer of compressed isosorbide dinitrate and hydralazine-containing particles.
10. The composition according to claim 9 , wherein the four populations of particles are provided in a rapidly dissolving dosage form.
11. A method for the treatment of angina, ischaemic heart disease, arterial hypertension or related disease conditions comprising administering a therapeutically effective amount of a composition according to claim 1 .
12. The composition according to claim 1 , wherein the particles incorporating a modified-release coating comprise a pH-dependent polymer coating which is effective in releasing a pulse of the active ingredient following a time delay of two to twelve hours.
13. The composition according to claim 12 , wherein the polymer coating comprises methacrylate copolymers.
14. The composition according to claim 4 , wherein the modified-release coating comprises a mixture of methacrylate and ammonio methacrylate copolymers in a ratio sufficient to achieve a pulse of the active ingredients following a time delay.
15. The composition according to claim 14 , wherein the ratio of methacrylate to ammonio methacrylate copolymers is between approximately 95:5 and 50:50.
16. The composition according to claim 1 , wherein the hydralazine comprises hydralazine hydrochloride.
17. The composition according to claim 9 , wherein the hydralazine comprises hydralazine hydrochloride.
18. The method according to claim 11 , wherein the hydralazine comprises hydralazine hydrochloride.